NASDAQ:PRDS Pardes Biosciences (PRDS) Stock Forecast, Price & News $2.16 0.00 (0.00%) (As of 09/12/2023) Add Compare Share Share Today's Range$2.16▼$2.1650-Day Range$2.09▼$2.1652-Week Range$0.75▼$3.93Volume400 shsAverage Volume359,530 shsMarket Capitalization$133.95 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Pardes Biosciences (NASDAQ:PRDS) StockPardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.Read More PRDS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRDS Stock News HeadlinesAugust 31, 2023 | finance.yahoo.comPardes Biosciences Announces Closing of Tender OfferAugust 28, 2023 | finance.yahoo.comMediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes BiosciencesSeptember 30, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 17, 2023 | finance.yahoo.comMediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences SharesAugust 3, 2023 | msn.comPardes Biosciences (PRDS) Price Target Decreased by 28.57% to 1.28July 19, 2023 | marketwatch.comPardes Biosciences Shares Rise 15% After Buyout Offer From MediPacificJuly 19, 2023 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pardes Bioscience, Inc. (PRDS)July 18, 2023 | msn.comJMP Securities Downgrades Pardes Biosciences (PRDS)September 30, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.July 17, 2023 | benzinga.comPRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to ShareholdersJuly 17, 2023 | msn.comPardes Biosciences stock rallies on buyout offer from MediPacificJuly 17, 2023 | benzinga.comWhy Pardes Biosciences Shares Are Rising MondayJuly 17, 2023 | markets.businessinsider.comPardes Biosciences To Be Acquired By MediPacific; Pardes Up In Pre-marketJuly 17, 2023 | finance.yahoo.comPardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value RightsJune 5, 2023 | finance.yahoo.comAll You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to BuyMay 17, 2023 | seekingalpha.comPardes Biosciences Seeking Strategic AlternativesMay 9, 2023 | markets.businessinsider.comPardes Biosciences (PRDS) Receives a Hold from SVB SecuritiesMay 6, 2023 | barrons.comPardes Biosciences Inc.May 6, 2023 | finanznachrichten.dePardes Biosciences, Inc: Pardes Biosciences Reports First Quarter 2023 Financial ResultsMay 5, 2023 | msn.comRecap: Pardes Biosciences Q1 EarningsMay 5, 2023 | finance.yahoo.comPardes Biosciences Reports First Quarter 2023 Financial ResultsApril 12, 2023 | benzinga.comAnalyst Rating: Will Pardes Biosciences Inc (PRDS) Stock Do Better Than the Market?April 7, 2023 | seekingalpha.comPardes Biosciences cut at Jefferies on COVID drug failureApril 4, 2023 | msn.comSVB Leerink Downgrades FS Development Corp II (PRDS)April 4, 2023 | markets.businessinsider.comSVB Securities downgrades Pardes Biosciences (PRDS) to a HoldApril 3, 2023 | msn.comPardes slumps ~10% after COVID drug trial failure prompts strategic reviewApril 3, 2023 | msn.comPardes Biosciences Looks For Alternatives After Failed COVID-19 StudySee More Headlines Receive PRDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PRDS Company Calendar Last Earnings8/04/2023Today9/30/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRDS CUSIPN/A CIK1822711 Webwww.pardesbio.com Phone415-649-8758FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.50 High Stock Price Forecast$5.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+62.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.36% Return on Assets-40.71% Debt Debt-to-Equity RatioN/A Current Ratio81.72 Quick Ratio81.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.51 per share Price / Book0.86Miscellaneous Outstanding Shares62,012,000Free Float36,711,000Market Cap$133.95 million OptionableNot Optionable Beta0.42 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Thomas G. Wiggans (Age 71)CEO & Chairman Comp: $859.4kDr. Uri A. Lopatin M.D. (Age 51)Founder & Director Comp: $786.96kMs. Heidi Henson CPA (Age 57)Chief Financial Officer Comp: $564.6kMs. Elizabeth Haber Lacy J.D. (Age 56)Gen. Counsel & Corp. Sec. Key CompetitorsParatek PharmaceuticalsNASDAQ:PRTKAtara BiotherapeuticsNASDAQ:ATRAKodiak SciencesNASDAQ:KODCara TherapeuticsNASDAQ:CARAAffimedNASDAQ:AFMDView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Bought 22,166 shares on 8/15/2023Ownership: 1.352%Western Standard LLCBought 482,874 shares on 8/15/2023Ownership: 0.779%RBF Capital LLCBought 150,000 shares on 8/15/2023Ownership: 0.242%Irenic Capital Management LPBought 48,751 shares on 8/15/2023Ownership: 0.079%Y Intercept Hong Kong LtdBought 47,469 shares on 8/15/2023Ownership: 0.077%View All Insider TransactionsView All Institutional Transactions PRDS Stock - Frequently Asked Questions Should I buy or sell Pardes Biosciences stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pardes Biosciences in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PRDS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRDS, but not buy additional shares or sell existing shares. View PRDS analyst ratings or view top-rated stocks. What is Pardes Biosciences' stock price forecast for 2023? 4 equities research analysts have issued 12 month target prices for Pardes Biosciences' shares. Their PRDS share price forecasts range from $2.00 to $5.00. On average, they anticipate the company's stock price to reach $3.50 in the next year. This suggests a possible upside of 62.0% from the stock's current price. View analysts price targets for PRDS or view top-rated stocks among Wall Street analysts. How have PRDS shares performed in 2023? Pardes Biosciences' stock was trading at $1.69 on January 1st, 2023. Since then, PRDS stock has increased by 27.8% and is now trading at $2.16. View the best growth stocks for 2023 here. When is Pardes Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our PRDS earnings forecast. How were Pardes Biosciences' earnings last quarter? Pardes Biosciences, Inc. (NASDAQ:PRDS) released its quarterly earnings data on Friday, August, 4th. The company reported ($0.18) EPS for the quarter. What is Pardes Biosciences' stock symbol? Pardes Biosciences trades on the NASDAQ under the ticker symbol "PRDS." How do I buy shares of Pardes Biosciences? Shares of PRDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pardes Biosciences' stock price today? One share of PRDS stock can currently be purchased for approximately $2.16. How much money does Pardes Biosciences make? Pardes Biosciences (NASDAQ:PRDS) has a market capitalization of $133.95 million. The company earns $-96,630,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. How can I contact Pardes Biosciences? Pardes Biosciences' mailing address is 900 LARKSPUR LANDING CIRCLE SUITE 150, SAN FRANCISCO CA, 94939. The official website for the company is www.pardesbio.com. The company can be reached via phone at 415-649-8758. This page (NASDAQ:PRDS) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pardes Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.